期刊文献+

miR-145联合替莫唑胺对U251胶质瘤细胞恶性行为的影响 被引量:7

下载PDF
导出
摘要 目的:研究miR-145联合替莫唑胺对胶质瘤细胞恶性行为的影响。方法:将miR-145类似物及抑制剂转染入U251胶质瘤细胞,通过RT-q PCR法检测细胞内miR-145表达水平;并联合替莫唑胺处理细胞,检测不同处理组U251细胞增殖、迁移和侵袭能力。结果:miR-145类似物联合替莫唑胺处理组的细胞恶性行为明显低于单纯使用miR-145类似物或替莫唑胺处理组,miR NA-145类似物联合替莫唑胺处理组的U251细胞增殖率、细胞迁移率分别为空白对照组的(11.42±6.13)%(t=16.821,P<0.05)、(21.47±10.68)%(t=7.835,P<0.05)、侵袭试验检测细胞为(510.2±189.5)个,显著低于对照组(t=7.128,P<0.05)。结论 :miR-145可增强替莫唑胺对U251细胞的体外恶性行为的抑制。
出处 《实用医学杂志》 CAS 北大核心 2016年第3期371-375,共5页 The Journal of Practical Medicine
  • 相关文献

参考文献10

  • 1FILIPOWICZ W, BHATTACHARYYA SN, SONENBERG N.Mechanisms of post-transcriptional regulation by microRNAs :are the answers in sight? [J]. Nat Rev Genet, 2008,9(2):102-114. 被引量:1
  • 2魏顺英,王春梅,王烈宏.MiR-145在上皮性卵巢癌组织中的表达及临床意义[J].实用医学杂志,2013,29(22):3724-3726. 被引量:8
  • 3RANI SB, RATHOD SS,KARTHIK S, et al, MiR-145functions as a tumor-suppressive RNA by targeting Sox9 andadducin 3 in human glioma cells [J]. Neuro Oncol, 2013,15(10): 1302-1316. 被引量:1
  • 4LAI A, TRAN A,NGHIEMPHU PL, et al. Phase II study ofbevacizumab plus temozolomide during and after radiationtherapy for patients with newly diagnosed glioblastomamultiforme [J]. J Clin Oncol, 2011,29(2): 142-148. 被引量:1
  • 5CHEN Y, HU F, ZHOU Y,et al. MGMT promoter methylationand glioblastoma prognosis : a systematic review and meta-analysis [J]. Arch Med Res, 2013,44(4): 281-290. 被引量:1
  • 6李晓兴,王之敏.替莫唑胺治疗神经胶质瘤的研究进展[J].实用医学杂志,2012,28(1):27-29. 被引量:18
  • 7LEE HK, FINNISS S, CAZACU S, et al. Mesenchymal stemcells deliver synthetic microRNA mimics to glioma cells andglioma stem cells and inhibit their cell migration and self-renewal [J]. Oncotarget,2013,4(2) : 346-361. 被引量:1
  • 8LEE, SJ, KIM SJ, SEO HH, et al. Over-expression of miR-145 enhances the effectiveness of HSVtk gene therapy formalignant glioma [J]. Cancer Lett, 2012,320(1): 72-80. 被引量:1
  • 9CUI SY, WANG R, CHEN LB. MicroRNA-145: a potenttumour suppressor that regulates multiple cellular pathways[J]. J Cell Mol Med,2014,18( 10) : 1913-1926. 被引量:1
  • 10马金阳,陈谦学.微小RNA-145在胶质瘤中的表达及其临床意义[J].中华实验外科杂志,2014,31(9):1871-1873. 被引量:5

二级参考文献51

  • 1Dehdashti A R, Hegi M E, Regli L, et al. A new trends in the medical management of glioblastoma multiforme: the role of temozolnmide chemotherapy [J]. Neurosurg Focus, 2006,20 (4) :E6. 被引量:1
  • 2Rosso L, Brock C S, Gallo J M, et al. A new model for prediction of drug distribution in tumor and normal tissues: pharmaeokinetics of temozolomide in glioma patients [J]. Cancer Res, 2009,69 ( 1 ) : 120-127. 被引量:1
  • 3Agarwala S S, Kirkwood J M. Temozolomide,a novel alkylating agent with activity in the central nervous system,may improve the treatment of advanced metastatic melanoma [J]. Oncologist,2000,5(2):144-151. 被引量:1
  • 4Hegi M E, Diserens A C, Godia T, et al. MGMT gene silencing and benefit from temozolomide in gioblastoma [J]. N Engl J Med,2005,352(,10):997-1003. 被引量:1
  • 5Chinot 0 L, Barrie M, Fuentes S, et al. Correlation between O6- methylguanine-DNA methyhransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide [ J ]. J Clin Oneol, 2007,25 ( 12 ) : 1470-1475. 被引量:1
  • 6Chalmers A J, Ruff E M, Martindale C,et al. Cytotoxic effects of temozolomide and radiation are additive- and schedule- dependent [J]. Int J Radiat Oneol Biol Phys,2009,75(5) : 1511- 1519. 被引量:1
  • 7Chamberlain M C, Glantz M J, Chalmers L, et al. Early necrosis following concurrent temozolomide and radiotherapy in adult patients with glioblastoma [J]. J Clin Oneol,2006,24 (18S): 1513. 被引量:1
  • 8Stupp R, Mason W P, van den Bent M J, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastorna [ J ]. N Engl J Med, 2005,352 (10) : 987-996. 被引量:1
  • 9D'Agostino G R, Balducci M, Anile C, et al. An analysis of two different schedules of radiochemotherapy with concomitant temozolomide in high grade glionaas [J]. J Clin Oneol,2007,25 (18S) : 2035. 被引量:1
  • 10Wick W, Steinbach J P, Kuker W M, et al. One week on/one week off:a novel active regimen of temozolomide for recurrent glioblastoma [J ]. Neurology, 2004,62 ( 11 ) : 2113-2115. 被引量:1

共引文献28

同被引文献35

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部